留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

预防和治疗高原病药物临床用药参考

马骏,  樊鹏程,  张强,  马慧萍,  王荣,  贾正平

downloadPDF
文章导航 > 药学实践与服务  > 2013 >  31(4): 246-250
马骏, 樊鹏程, 张强, 马慧萍, 王荣, 贾正平. 预防和治疗高原病药物临床用药参考[J]. 药学实践与服务, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
引用本文: 马骏, 樊鹏程, 张强, 马慧萍, 王荣, 贾正平. 预防和治疗高原病药物临床用药参考[J]. 药学实践与服务, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
shu
MA Jun, FAN Peng-cheng, ZHANG Qiang, MA Hui-ping, WANG Rong, JIA Zheng-ping. Clinical pharmacology in the prophylaxis and treatment of high-altitude illness[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
Citation: MA Jun, FAN Peng-cheng, ZHANG Qiang, MA Hui-ping, WANG Rong, JIA Zheng-ping. Clinical pharmacology in the prophylaxis and treatment of high-altitude illness[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
shu

预防和治疗高原病药物临床用药参考

doi: 10.3969/j.issn.1006-0111.2013.04.002

  • 兰州军区兰州总医院药剂科, 甘肃 兰州 730050

基金项目: 国家科技重大专项(军特药保密专项)(2008ZXJ09014-010).

Clinical pharmacology in the prophylaxis and treatment of high-altitude illness

  • Department of Pharmacy, General Hospital of Lanzhou Command, Lanzhou 730050, China

  • 摘要: 本文针对乙酰唑胺、地塞米松、硝苯地平、西地那非和沙美特罗5种药物,在治疗急性高原病、高原脑水肿、高原肺水肿及伴随其他疾病情况下的高原病,就如何选择和使用这些药物进行综述。讨论了正常的给药剂量,当病人患有肾功能不全、肝功能不全、其他疾病以及存在药物相互作用情况下,就如何选择用药和剂量调整进行阐述。通过对上述问题的充分考虑,医生在救治病人时可以提高合理用药水平和治疗成功率,使病人安全愉快地在高原旅行。
    Abstract: The use choice of acetazolamide, dexamethasone, nifedipine, sildenafil, and salmeterol in the management of altitude illness such as acute mountain sickness, high-altitude cerebral edema, high-altitude pulmonary edema, and with underlying medical problems were reviewed. The indications and dosing recommendations for individuals without underlying disease were discussed, and drug selection or dosing regimens were considered which would be affected by the presence of renal insufficiency, hepatic insufficiency, other important medical conditions, and the potential for drug interactions. These issues should be taken adequate consideration; so clinicians could increase the chances that properly healed patients with underlying medical conditions who could enjoy a safe trip to high altitude.
  • [1] Maggiorini M, Brunner-La RHP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema:a randomized trial[J]. Ann Intern Med, 2006, 145:497.
    [2] Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema[J]. N Engl J Med, 2002, 346:1631.
    [3] Teppema LJ, Balanos GM, Steinback CD, et al. Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxia[J]. Am J Respir Crit Care Med, 2007, 175:277.
    [4] Hackett PH, Roach RC. High-altitude illness[J]. N Engl J Med, 2001, 345:107.
    [5] Luks AM, Swenson ER. Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness[J]. Chest, 2008, 133:744.
    [6] Pepys MB. Acetazolamide and renal stone formation[J]. Lancet, 1970, 1:837.
    [7] van Bortel L, Bohm R, Mooij J, et al. Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure[J]. Eur J Clin Pharmacol, 1989, 37:185.
    [8] Swan SK, Bennett WM. Drug dosing guidelines in patients with renal failure[J]. West J Med, 1992, 156:633.
    [9] Forgue ST, Phillips DL, Bedding AW, et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics[J]. Br J Clin Pharmacol, 2007, 63:24.
    [10] Muirhead GJ, Wilner K, Colburn W, et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil[J]. Br J Clin Pharmacol, 2002, 53(suppl 1):21S.
    [11] Grossman EB, Swan SK, Muirhead GJ, et al. The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients[J]. Kidney Int, 2004, 66:367.
    [12] Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol[J]. Clin Pharmacokinet, 2002, 41:19.
    [13] Dawson AM, De Groote J, Rosenthal WA, et al. The effects of diamox ammonia metabolism in liver disease[J]. Clin Sci (Lond), 1957, 16:413.
    [14] Ene MD, Roberts CJ. Pharmacokinetics of nifedipine after oral administration in chronic liver disease[J]. J Clin Pharmacol, 1987, 27:1001.
    [15] Kleinbloesem CH, van Harten J, Wilson JP, et al. Nifedipine:kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration[J]. Clin Pharmacol Ther, 1986, 40:21.
    [16] Callejas RJL, Salmeron Escobar J, Gonzalez-Calvin J, et al. Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil[J]. Liver Transpl, 2006, 12:690.
    [17] Wang YW, Lin HC, Yang YY, et al. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension[J]. J Gastroenterol, 2006, 41:593.
    [18] Finley DS, Lugo B, Ridgway J, et al. Fatal variceal rupture after sildenafil use:report of a case[J]. Curr Surg, 2005, 62:55.
    [19] Manchee GR, Eddershaw PJ, Ranshaw LE, et al. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A[J]. Drug Metab Dispos, 1996, 24:555.
    [20] Swenson ER. Carbonic anhydrase inhibitors and ventilation:a complex interplay of stimulation and suppression[J]. Eur Respir J, 1998, 12:1242.
    [21] Coudon WL, Block AJ. Acute respiratory failure precipitated by a carbonic anhydrase inhibitor[J]. Chest, 1976, 69:112.
    [22] Brubaker PL. Adventure travel and type 1 diabetes:the complicating effects of high altitude[J]. Diabetes Care, 2005, 28:2563.
    [23] Stuiver PC, Goud TJ. Corticosteroids and liver amoebiasis[J]. BMJ, 1978, 2:394.
    [24] Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population[J]. Clin Microbiol Rev, 2004, 17:208.
    [25] Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease[J]. N Engl J Med, 1983, 309:21.
    [26] Wu TY, Liu JL. Alcohol and aspirin in combination with dexamethasone causes gastrointestinal bleeding at high altitude[J]. Wilderness Environ Med, 2006, 17:69.
    [27] Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease:a randomized crossover trial[J]. JAMA, 2002, 287:719.
    [28] Fox KM, Thadani U, Ma PT, et al. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina[J]. Eur Heart J, 2003, 24:2206.
    [29] Petersen KU, Jaspersen D. Medication-induced oesophageal disorders[J]. Expert Opin Drug Saf, 2003, 2:495.
    [30] Sweeney KR, Chapron DJ, Brandt JL, et al. Toxic interaction between acetazolamide and salicylate:case reports and a pharmacokinetic explanation[J]. Clin Pharmacol Ther, 1986, 40:518.
    [31] Hill JB. Experimental salicylate poisoning:observations on the effects of altering blood pH on tissue and plasma salicylate concentrations[J]. Pediatrics, 1971, 47:658.
    [32] Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine:an update[J]. Clin Pharmacokinet, 1996, 31:198.
    [33] Tabbara KF, Al-Faisal Z, Al-Rashed W. Interaction between acetazolamine and cyclosporine[J]. Arch Ophthalmol, 1998, 116:832.
    [34] Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives[J]. Biomed Pharmacother, 1986, 40:301.
    [35] Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs[J]. Am J Cardiovasc Drugs, 2004, 4:281.
    [36] Kaplan RC, Heckbert SR, Koepsell TD, et al. Use of calcium-channel blockers and risk of hospitalized gastrointestinal tract bleeding[J]. Arch Intern Med, 2000, 160:1849.
    [37] Wu TY, Ding SQ, Liu JL, et al. High-altitude gastrointestinal bleeding:an observation in Qinghai-Tibetan railroad construction workers on Mountain Tanggula[J]. World J Gastroenterol, 2007, 13:774.
    [38] Smith M, Lin KM, Zheng YP. An open-trial of nifedipineherb interactions:nifedipine with St. John's wort, ginseng, or gingko biloba[J]. Clin Pharmacol Ther, 2001, 69:86.
    [39] Demaziere J, Fourcade JM, Busseuil CT, et al. The hazards of chloroquine self prescription in West Africa[J]. J Toxicol Clin Toxicol, 1995, 33:369.
  • [1] 徐璐璐, 刘爱军.  丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2024, 42(12): 1-8. doi: 10.12206/j.issn.2097-2024.202312027
    [2] 陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾.  基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
    [3] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [4] 杨嘉宁, 赵一颖, 肖伟.  七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
    [5] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
    [6] 桂明珠, 李静, 李志玲.  儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
    [7] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
    [8] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [9] 张莲卿, 骆岩, 杨提, 姚佳晨, 李文艳.  基于FAERS数据库的艾塞那肽微球不良事件信号挖掘与研究 . 药学实践与服务, 2024, 42(10): 445-450. doi: 10.12206/j.issn.2097-2024.202403057
    [10] 杨凤艳, 张月, 陈恩贤, 缪雪蓉, 魏凯.  瑞马唑仑临床应用研究进展 . 药学实践与服务, 2024, 42(9): 365-374. doi: 10.12206/j.issn.2097-2024.202405026
    [11] 史生辉, 石飞, 雷琼, 王亚峰, 吴雪花.  青藏高原肺结核合并念珠菌感染患者的病原菌分布特点及耐药率分析 . 药学实践与服务, 2024, 42(6): 260-262, 272. doi: 10.12206/j.issn.2097-2024.202304014
    [12] 石晓萍, 吕迁洲, 李晓宇, 许青.  泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3610
  • HTML全文浏览量:  862
  • PDF下载量:  83
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-08-22
  • 修回日期:  2012-12-18

预防和治疗高原病药物临床用药参考

doi: 10.3969/j.issn.1006-0111.2013.04.002
  • 兰州军区兰州总医院药剂科, 甘肃 兰州 730050
    • 基金项目:  国家科技重大专项(军特药保密专项)(2008ZXJ09014-010).
  • 收稿日期: 2012-08-22
  • 修回日期: 2012-12-18

摘要: 本文针对乙酰唑胺、地塞米松、硝苯地平、西地那非和沙美特罗5种药物,在治疗急性高原病、高原脑水肿、高原肺水肿及伴随其他疾病情况下的高原病,就如何选择和使用这些药物进行综述。讨论了正常的给药剂量,当病人患有肾功能不全、肝功能不全、其他疾病以及存在药物相互作用情况下,就如何选择用药和剂量调整进行阐述。通过对上述问题的充分考虑,医生在救治病人时可以提高合理用药水平和治疗成功率,使病人安全愉快地在高原旅行。

English Abstract

马骏, 樊鹏程, 张强, 马慧萍, 王荣, 贾正平. 预防和治疗高原病药物临床用药参考[J]. 药学实践与服务, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
引用本文: 马骏, 樊鹏程, 张强, 马慧萍, 王荣, 贾正平. 预防和治疗高原病药物临床用药参考[J]. 药学实践与服务, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
shu
MA Jun, FAN Peng-cheng, ZHANG Qiang, MA Hui-ping, WANG Rong, JIA Zheng-ping. Clinical pharmacology in the prophylaxis and treatment of high-altitude illness[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
Citation: MA Jun, FAN Peng-cheng, ZHANG Qiang, MA Hui-ping, WANG Rong, JIA Zheng-ping. Clinical pharmacology in the prophylaxis and treatment of high-altitude illness[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(4): 246-250. doi: 10.3969/j.issn.1006-0111.2013.04.002
shu

    全文HTML

参考文献 (39)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计